NextCell Pharma AB (NXTCL) - Cash Flow Conversion Efficiency

Latest as of August 2025: -0.162x

Based on the latest financial reports, NextCell Pharma AB (NXTCL) has a cash flow conversion efficiency ratio of -0.162x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.77 Million ≈ $-1.16 Million USD) by net assets (Skr66.39 Million ≈ $7.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

NextCell Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how NextCell Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NXTCL current and long-term liabilities for a breakdown of total debt and financial obligations.

NextCell Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NextCell Pharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ornapaper Bhd KLSE:5065	0.087x
Indiana Resources Ltd AU:IDA	-0.785x
Origin Agritech Ltd NASDAQ:SEED	0.216x
INVO Fertility, Inc. NASDAQ:IVF	-0.304x
Mg Internation PA:ALMGI	0.006x
Nixxy, Inc. NASDAQ:NIXX	-0.096x
Volex Plc LSE:VLX	0.052x
Putprop Ltd JSE:PPR	0.010x

Annual Cash Flow Conversion Efficiency for NextCell Pharma AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of NextCell Pharma AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of NextCell Pharma AB.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	Skr66.39 Million ≈ $7.14 Million	Skr-38.86 Million ≈ $-4.18 Million	-0.585x	-4.75%
2024-08-31	Skr67.60 Million ≈ $7.27 Million	Skr-37.78 Million ≈ $-4.07 Million	-0.559x	+3.43%
2023-08-31	Skr75.73 Million ≈ $8.15 Million	Skr-43.83 Million ≈ $-4.72 Million	-0.579x	-100.73%
2022-08-31	Skr115.54 Million ≈ $12.43 Million	Skr-33.31 Million ≈ $-3.58 Million	-0.288x	-69.19%
2021-08-31	Skr150.09 Million ≈ $16.15 Million	Skr-25.58 Million ≈ $-2.75 Million	-0.170x	+76.44%
2020-08-31	Skr26.22 Million ≈ $2.82 Million	Skr-18.96 Million ≈ $-2.04 Million	-0.723x	+24.99%
2019-08-31	Skr22.96 Million ≈ $2.47 Million	Skr-22.13 Million ≈ $-2.38 Million	-0.964x	+64.13%
2018-08-31	Skr5.04 Million ≈ $542.53K	Skr-13.55 Million ≈ $-1.46 Million	-2.688x	-246.01%
2017-08-31	Skr19.07 Million ≈ $2.05 Million	Skr-14.82 Million ≈ $-1.59 Million	-0.777x	+52.74%
2016-08-31	Skr6.76 Million ≈ $728.00K	Skr-11.12 Million ≈ $-1.20 Million	-1.644x	-106.93%
2015-08-31	Skr9.77 Million ≈ $1.05 Million	Skr-7.76 Million ≈ $-835.27K	-0.794x	--

About NextCell Pharma AB

ST:NXTCL Sweden Biotechnology

Market Cap

$13.21 Million

Skr122.76 Million SEK

Market Cap Rank

#26184 Global

#560 in Sweden

Share Price

Skr1.10

Change (1 day)

-4.01%

52-Week Range

Skr0.67 - Skr1.69

All Time High

Skr29.60